Combination therapy with anti-ErbB3 monoclonal antibodies and EGFR TKIs potently inhibits Non-small Cell Lung Cancer

Personalized therapy of advanced non-small cell lung cancer (NSCLC) has been improved by the introduction of EGFR tyrosine kinase inhibitors (TKIs), gefitinib and erlotinib. EGFR TKIs induce dramatic objective responses and increase survival in patients bearing sensitizing mutations in the EGFR intr...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Noto, Alessia, De Vitis, Claudia, Roscilli, Giuseppe, Fattore, Luigi, Malpicci, Debora, Marra, Emanuele, Luberto, Laura, D'Andrilli, Antonio, Coluccia, Pierpaolo, Giovagnoli, Maria Rosaria, Normanno, Nicola, Ruco, Luigi, Aurisicchio, Luigi, Mancini, Rita, Ciliberto, Gennaro
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2013
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3787155/
https://ncbi.nlm.nih.gov/pubmed/23896512
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados